VEGFA and renal cell carcinoma: FBXO22 was previously shown to have no effect on renal cell carcinoma (RCC) cell proliferation, but FBXO22 was shown to limit RCC cell motility and reverse epithelial-to-mesenchymal transition (EMT) by increasing TIMP-1 activity, decreasing MMP-9 expression, and reducing VEGF secretion (16).